Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency.
Interfering with the activity of β-secretase to reduce the production of Aβ peptides is a conceivable therapeutic strategy for Alzheimer's disease. However, the development of efficient yet safe inhibitors is hampered by secondary effects, usually linked to the indiscriminate inhibition of other substrates' processing by the targeted enzyme. Based on the spatial compartmentalization of the cleavage of the amyloid precursor protein by β-secretase, we hypothesized that by exploiting the endocytosis receptor low-density lipoprotein receptor-related protein it would be possible to direct an otherwise cell-impermeable inhibitor to the endosomes of neurons, boosting the drug's efficacy and importantly, sparing the off-target effects. We used the transport peptide Angiopep to build an endocytosis-competent conjugate and found that although the peptide facilitated the inhibitor's internalization into neurons and delivered it to the endosomes, the delivery was not efficient enough to potently reduce β-secretase activity at the cellular level. This is likely connected to the finding that in the cell lines we used, Angiopep's internalization was not mediated by its presumed receptor to a significant extent. Additionally, Angiopep exploited different internalization mechanisms when applied alone or when conjugated to the inhibitor, highlighting the impact that drug conjugation can have on transport peptides.
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Jong Ah
JA
Kim
Institute of Chemical and Bioengineering, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Tommaso
T
Casalini
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Davide
D
Brambilla
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Jean-Christophe
JC
Leroux
Bioconjug Chem. 2005 Nov-Dec;16(6):1399-410
16287236
J Cell Sci. 2003 Aug 15;116(Pt 16):3339-46
12829747
J Biol Chem. 2003 Sep 5;278(36):34141-9
12773529
Methods Enzymol. 2008;438:77-93
18413242
Sci Transl Med. 2011 May 25;3(84):84ra43
21613622
Alzheimers Res Ther. 2014 Dec 24;6(9):89
25621019
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41
11517324
Phys Rev Lett. 2008 Jan 18;100(2):020603
18232845
J Control Release. 2005 Jan 20;102(1):247-53
15653149
Br J Pharmacol. 2008 Sep;155(2):185-97
18574456
J Biol Chem. 2005 Apr 15;280(15):15300-6
15687490
Science. 2002 Jul 19;297(5580):353-6
12130773
Mol Neurobiol. 2012 Apr;45(2):366-78
22415442
Pharm Res. 2009 Nov;26(11):2486-94
19774344
J Biol Chem. 2005 May 6;280(18):17777-85
15749709
J Neurosci. 2015 Jan 21;35(3):1199-210
25609634
J Chem Theory Comput. 2012 Jul 10;8(7):2189-92
26588950
J Clin Invest. 2000 Dec;106(12):1489-99
11120756
Nat Med. 2008 Aug;14(8):837-42
18568035
Angew Chem Int Ed Engl. 2012 Dec 7;51(50):12454-8
23129324
J Clin Invest. 2014 Mar;124(3):1199-213
24531547
J Biol Chem. 2010 Jan 8;285(2):1500-7
19858185
J Cell Sci. 2004 Oct 1;117(Pt 21):5071-8
15383619
Nat Med. 2004 Mar;10(3):310-5
14770178
Science. 2012 Mar 23;335(6075):1503-6
22323736
J Neurochem. 2008 Aug;106(4):1534-44
18489712
N Engl J Med. 2013 Jul 25;369(4):341-50
23883379
Chembiochem. 2007 Nov 23;8(17):2078-91
17963207
FASEB J. 2007 Sep;21(11):2742-52
17463224
J Biol Chem. 2011 Jul 8;286(27):23967-74
21576249
Cell Rep. 2016 Mar 8;14 (9):2127-41
26923602
J Cell Sci. 1994 Mar;107 ( Pt 3):719-26
8006085
J Chem Theory Comput. 2012 Sep 11;8(9):3314-21
26605738
J Biol Chem. 2000 Mar 10;275(10):7410-5
10702315
Nat Med. 1995 Dec;1(12):1291-6
7489411
Physiol Rev. 2008 Jul;88(3):887-918
18626063
Org Biomol Chem. 2012 Oct 3;10(41):8216-35
22930158
J Biol Chem. 2010 Dec 31;285(53):41443-54
20961856
Angew Chem Int Ed Engl. 2012 Oct 22;51(43):10795-9
23023944
J Pharmacol Exp Ther. 2008 Mar;324(3):1064-72
18156463
J Biol Chem. 1995 Aug 11;270(32):19188-96
7642587
Science. 2008 Apr 25;320(5875):520-3
18436784
J Med Chem. 2002 Jan 17;45(2):259-62
11784130
Mol Ther. 2004 Dec;10(6):1011-22
15564133
J Neurosci. 2011 Nov 16;31(46):16507-16
22090477
Mol Ther. 2003 Aug;8(2):284-94
12907151
Cell. 1995 Jul 28;82(2):331-40
7543026
Curr Biol. 2001 Aug 21;11(16):1288-93
11525745
J Neurosci. 2013 May 1;33(18):7856-69
23637177
J Neurochem. 2014 Jul;130(1):4-28
24646365
J Biol Chem. 2009 Feb 6;284(6):3793-803
19074428